Mersana Therapeutics Inc

NASDAQ:MRSN  
5.02
+0.11 (+2.24%)
Products

Mersana Therapeutics Announces FDA Grant Of Orphan Drug Designation To XMT-2056

Published: 05/19/2022 11:08 GMT
Mersana Therapeutics Inc (MRSN) - Mersana Therapeutics Announces FDA Grant of Orphan Drug Designation to Xmt-2056 for the Treatment of Gastric Cancer.